Compare Merck & Co., Inc. (MRK) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Toyota Motor Corp — how do they compare? Merck & Co., Inc. trades at $142.05 (market cap $352.29B), while Toyota Motor Corp trades at $184.37 (market cap $216.99B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Toyota Motor Corp pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Toyota Motor Corp for 116 Days on average.
| MRK | TM | |
|---|---|---|
Market Cap | $352.29B | $216.99B |
Volume | 6,348,796 | 314,929 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $248.29 |
52-Week Low | $82.49 | $166.50 |
Typical Hold Time | 98 Days | 116 Days |
Enterprise Value | $399.05B | $410.32B |
Dividend Yield | 2.38% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals but attractive valuation metrics including P/E of 8.22 and P/B of 0.92. The company reported strong Q2 2026 earnings beat with EPS of $7.57 versus $4.68 expected, though revenue growth has moderated to 6.5% year-over-year. Recent news highlights Toyota's expanding electrified vehicle lineup and U.S. market share gains, while facing production challenges from Thailand floods and China sales weakness.
Toyota presents a value opportunity with solid profitability (8.63% net margin) and consistent earnings beats, but faces near-term headwinds from production disruptions and competitive pressures. Analyst consensus leans cautious with 62.5% hold ratings, suggesting the stock may consolidate near current levels despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
